Countries such as China and India are expected to lead the market. The ageing population and the increasing prevalence of ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer ...

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

A patient being treated for a brain bleed at St. Mary Medical Center last fall was given more than twice the necessary amount of an anti-blood clot medication after a nurse incorrectly reported their ...

Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

Objective: To provide recommendations, policies, and procedures pertaining to the provision of optimized anticoagulation therapy designed to achieve desired clinical endpoints while minimizing the ...

The California Ecosystems Protection Act (A.B. 1788) places important restrictions on the use of super-toxic rodenticides, known as second-generation anticoagulant rodenticides, to protect the state’s ...

The California Ecosystems Protection Act of 2023, or Assembly Bill 1322, will place a moratorium on the first-generation anticoagulant rodenticide diphacinone, a toxic rat poison still on the market ...